Relapsed or Refractory ALL
Some patients still have leukemia cells in their bone marrow after ALL treatment. This is called refractory leukemia. Some patients have a return of ALL cells in the marrow and a decrease in normal blood cells after remission. This is called a relapse.
The following drug is FDA approved to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). For more information, click on the link.
- Blinatumomab (BlincytoTM)
Additional treatment options for refractory ALL include:
- treatment with drugs not used during your past treatment
- a clinical trial
- an allogeneic stem cell transplantation
If you have relapsed ALL, you may be given more chemotherapy with the same or different drugs used previously during your treatment. Some patients may also have a stem cell transplantation or be a part of a clinical trial.
Your therapy options depend on two factors:
- your remission's duration
- the cytogenetic findings that reveal abnormal changes to the structure of chromosomes in your leukemia cells